EMA/128416/2012

European Medicines Agency decision

P/0042/2012

of 28 February 2012

on the agreement of a paediatric investigation plan and on the granting of a waiver for clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocouture) (EMEA-001039-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0042/2012

of 28 February 2012

on the agreement of a paediatric investigation plan and on the granting of a waiver for clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocouture) (EMEA-001039-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Merz Pharmaceuticals GmbH on 14 March 2011 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 January 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocouture), powder for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocouture), powder for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 3

This decision is addressed to Merz Pharmaceuticals GmbH, Eckenheimer Landstraße 100, 60318 Frankfurt/Main, Germany.

Done at London, 28 February 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/906311/2011

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMEA-001039-PIP01-10

Scope of the application

Active substance(s):

Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins

Invented name:

Xeomin

Bocouture

Condition(s):

Treatment of muscle spasticity

Treatment of dystonia

Treatment of muscle-induced wrinkles

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for solution for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

Merz Pharmaceuticals GmbH

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Merz Pharmaceuticals GmbH submitted for agreement to the European Medicines Agency on 14 March 2011 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 20 April 2011.

Supplementary information was provided by the applicant on 24 October 2011.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population, and Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 13 January 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of muscle spasticity

The waiver applies to:

- Preterm newborn infants, Term newborn infants (from birth to less than 28 days) an infants and toddlers (from 28 days to less than 24 months);
- for powder for solution for injection, intramuscular use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

1.2. Condition: Treatment of dystonia

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age;
- for powder for solution for injection, intramuscular use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

1.3. Condition: Treatment of muscle-induced wrinkles

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age;
- for powder for solution for injection, intramuscular use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of muscle spasticity

2.1.1. Indication(s) targeted by the PIP:

Treatment of muscle spasticity in cerebral palsy

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for solution for injection

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	2	Study 1. Prospective, multicenter, randomised, double-blind, parallel-group, two dose superiority controlled trial to evaluate efficacy of Clostridium Botulinum neurotoxin type A (150 kD), (high versus low dose) for the treatment of lower limb (LL) spasticity in children from 2 to less than 18 years with cerebral palsy (CP). Study 2. Open-label, non-controlled, multicenter long-term trial to evaluate the safety of Clostridium Botulinum neurotoxin type A (150 kD) for the treatment of spasticity in the upper and/or lower limb in children from 2 to less than 18 years of age with cerebral palsy (CP).

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By July 2016
Deferral for one or more studies contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of muscle spasticity

   Authorised indications:

   Treatment of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adult patients, in association with drug Xeomin

2. Treatment of dystonia

   Authorised indications:

   Treatment of cervical dystonia of a predominantly rotational form (spasmodic torticollis) in adult patients, *in association with drug* Xeomin

   Treatment of blepharospasmus in adult patients, *in association with drug* Xeomin

3. Treatment of muscle-induced wrinkles

   Authorised indications:

   Treatment of the appearance of moderate to severe vertical lines between the eyebrows seen at frown (glabellar frown lines) in adults below 65 years when the severity of these lines has an important psychological impact for the patient, in association with drug Bocouture

Invented name	**Strength**	**Pharmaceutical form**	**Route of administration**
Xeomin	50 U, 100 U	Powder for solution for injection	Intramuscular use
Bocouture	50 U	Powder for solution for injection	Intramuscular use